北京商报讯（记者丁宁）11月27日晚间，迈得医疗（688310）发布公告称，公司于11月27日收到公司董 事长、实际控制人林军华《关于提议迈得医疗工业设备股份有限公司回购公司股份的函》。 公告显示，基于对公司未来发展的信心和对公司价值的认可，为有效维护广大股东利益，增强投资者信 心，在综合考虑公司财务状况以及未来盈利能力的情况下，公司董事长、实际控制人林军华提议公司以 首次公开发行股票超募资金或自有资金回购部分公司股份，用于减少公司注册资本。回购股份的资金总 额不低于2000万元（含），不超过4000万元（含）。 （文章来源：北京商报） ...

Group 1 - The core point of the article is that Maide Medical (688310) has proposed a share buyback plan, reflecting the confidence of its chairman in the company's future development and value [1] - As of November 27, 2025, Maide Medical's stock closed at 16.79 yuan, up 4.81% from the previous trading day, with a total market capitalization of 2.791 billion yuan [1] - The proposed buyback will utilize either excess funds or the company's own funds to repurchase A-shares, with a total amount between 20 million yuan and 40 million yuan, and a buyback price not exceeding 150% of the average trading price over the previous 30 trading days [1] Group 2 - The buyback period is set to be within 12 months from the date of approval by the shareholders' meeting [1] - The chairman, Lin Junhua, has committed to promoting the necessary review procedures and voting in favor of the proposal [1]

Group 1 - The core point of the article is that Maide Medical announced a proposal by its chairman and actual controller, Lin Junhua, to repurchase a portion of the company's shares using either the proceeds from its initial public offering or its own funds to reduce the registered capital of the company [1] - The total amount of funds for the share repurchase will be no less than 20 million yuan (including) and no more than 40 million yuan (including) [1] - The repurchase will be conducted through centralized bidding transactions, and the repurchase price will not exceed 150% of the average trading price of the company's shares over the 30 trading days prior to the board's resolution on the repurchase [1]

Group 1 - The core point of the article is that Maide Medical announced a share buyback proposal by its chairman and actual controller Lin Junhua, with a budget of 20 million to 40 million yuan [1] - The buyback price will not exceed 150% of the average trading price of the company's stock over the 30 trading days prior to the board's resolution [1]

Group 1 - The core point of the article is that Maide Medical announced a share buyback proposal with a total funding amount between RMB 20 million and RMB 40 million [1] - The revenue composition for Maide Medical in 2024 is 98.7% from specialized equipment manufacturing and 1.3% from other businesses [1] - As of the report, Maide Medical has a market capitalization of RMB 2.8 billion [1]

迈得医疗11月27日公告，公司董事长、实控人林军华提议公司使用首次公开发行股票超募资金或自有资 金通过集中竞价交易方式回购公司已发行的部分人民币普通股（A股）股票，用于减少公司注册资本。 回购资金总额不低于人民币2000万元（含），不超过人民币4000万元（含）。回购价格上限不高于董事 会通过回购决议前三十个交易日公司股票交易均价的150%，具体以董事会审议通过的回购方案为准。 ...

Core Viewpoint - The company proposes to repurchase a portion of its shares using funds from its initial public offering or its own funds to reduce registered capital [1] Group 1 - The chairman and actual controller of the company, Lin Junhua, has suggested the share repurchase plan [1] - The total amount for the share repurchase will not be less than RMB 20 million and not exceed RMB 40 million [1] - The repurchase period is set to be within 12 months from the date of approval by the company's shareholders' meeting [1]

格隆汇11月27日丨迈得医疗(688310.SH)公布,公司于2025年11月27日收到公司董事长、实际控制人林军 华先生《关于提议迈得医疗工业设备股份有限公司回购公司股份的函》。林军华先生提议公司以首次公 开发行股票超募资金或自有资金回购部分公司股份，用于减少公司注册资本。回购资金总额不低于人民 币2000万元(含)，不超过人民币4000万元(含)。 ...

人民财讯11月27日电，迈得医疗(688310)11月27日公告，公司董事长、实际控制人林军华提议公司以首 次公开发行股票超募资金或自有资金回购部分公司股份，用于减少公司注册资本。回购股份的资金总额 不低于2000万元(含)，不超过4000万元(含)；回购股份的方式为集中竞价交易；回购股份的价格不高于 公司董事会通过回购股份决议前30个交易日公司股票交易均价的150%。 ...

智通财经APP讯，迈得医疗(688310.SH)发布公告，公司于2025年11月27日收到公司董事长、实际控制人 林军华先生《关于提议迈得医疗工业设备股份有限公司回购公司股份的函》，回购股份的资金总额不低 于2000万元(含)，不超过4000万元(含)，将用于减少公司注册资本。 ...